Background: MRI-guided laser interstitial thermal therapy (MRgLITT) is a new minimally invasive treatment for temporal lobe epilepsy (TLE), with limited effectiveness data. It is unknown if the cost savings associated with shorter hospitalization could offset the high equipment cost of MRgLITT. We examined the cost-utility of MRgLITT versus surgery for TLE from healthcare payer perspective, and the value of additional research to inform policy decision on MRgLITT.
Methods: We developed a microsimulation model to evaluate quality adjusted life years (QALYs), costs, and incremental cost-effectiveness ratio (ICER) of MRgLITT versus surgery in TLE, assuming life-time horizon and 1.5% discount rate. Model inputs were derived from the literature. We conducted threshold and sensitivity analyses to examine parameter uncertainties, and expected value of partial perfect information analyses to evaluate the expected monetary benefit of eliminating uncertainty on probabilities associated with MRgLITT.
Results: MRgLITT yielded 0.08 more QALYs and cost $7,821 higher than surgery, with ICER of $94,350/QALY. Influential parameters that could change model outcomes include probabilities of becoming seizure-free from disabling seizures state and returning to disabling seizures from seizure-free state 5 years after surgery and MRgLITT, cost of MRgLITT disposable equipment, and utilities of disabling seizures and seizure-free states of surgery and MRgLITT. The cost-effectiveness acceptability curve showed surgery was preferred in more than 50% of iterations. The expected monetary benefit of eliminating uncertainty for probabilities associated with MRgLITT was higher than for utilities associated with MRgLITT.
Conclusions: MRgLITT resulted in more QALYs gained and higher costs compared to surgery in the base-case. The model was sensitive to variations in the cost of MRgLITT disposable equipment. There is value in conducting more research to reduce uncertainty on the probabilities and utilities of MRgLITT, but priority should be given to research focusing on improving the precision of estimates on effectiveness of MRgLITT.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6867628 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0224571 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Lobectomy vs. MRgLITT in Temporal Lobe Epilepsy (TLE): A Pilot Study Investigating Vestibulo-Spatial Functions.
J Clin Med
December 2024
Degenerative and Chronic Diseases of the Faculty of Health Sciences (FGW), University Potsdam, 14469 Potsdam, Germany.
: About 65 million people worldwide are affected by epilepsy, with temporal lobe epilepsy being the most common type resistant to drugs and often requiring surgical treatment. Although open surgical approaches, such as temporal lobectomy, have been the method of choice for decades, minimally invasive MRgLITT has demonstrated promising results. However, it remains unknown whether patients who underwent one of these two approaches would show better performance on vestibulo-spatial tasks.
View Article and Find Full Text PDFOutcome of Surgery for Hypothalamic Hamartoma-Related Epilepsy: A Systematic Review and Individual Participant Data Meta-Analysis.
Neurology
December 2024
From the Department of Medicine (F.N.), Université de Montréal, Québec, Canada; David Geffen School of Medicine at the University of California, Los Angeles (K.G., A.F.); Warren Alpert Medical School of Brown University (J.-S.C.), Providence, RI; Division of Neurology (A.H.), Department of Pediatrics, Sainte-Justine University Hospital Centre, Montréal; Brain and Development Research Axis (A.H., A.G.W.), Centre de Recherche Azrieli du CHU Sainte-Justine, Montréal; Department of Neuroscience (M.R.K., D.K.N.), Université de Montréal; Research Centre of the University of Montreal Hospital Center (CRCHUM) (M.R.K., D.K.N.); Division of Neurology (M.R.K., D.K.N.), University of Montreal Hospital Center (CHUM); Laboratoire d'Imagerie Optique en Neurodéveloppement (LIONlab) (A.G.), CHU Sainte-Justine Research Center, Montréal; Cerebrum (A.G.), Department of Psychology, Université de Montréal, Québec, Canada; Department of Neurological Surgery (N.S.), Northwestern University Feinberg School of Medicine, Chicago, IL; Neuroscience Advanced Clinical Imaging Service (NACIS) (J.Y.-M.Y.), Department of Neurosurgery, The Royal Children's Hospital; Department of Paediatrics (J.Y.-M.Y.), The University of Melbourne; Neuroscience Research (J.Y.-M.Y.), Murdoch Children's Research Institute, Melbourne, Australia; Hope for Hypothalamic Hamartomas Organization (L.S., E.W.); APHM (B.D., D.S.), Timone Hospital, Epileptology and Cerebral Rhythmology, Marseille, France; Jane and John Justin Institute for Mind Health (M.S.P.), Cook Children's Health Care System, Fort Worth, TX; Division of Neurosurgery (K.M., G.M.I.), Hospital for Sick Children; Neurosciences & Mental Health (K.M., G.M.I.), SickKids Research Institute, Toronto, Ontario, Canada; Center for Neuroscience Research (W.D.G.), and Department of Neurology (W.D.G.), Children's National Hospital, George Washington University School of Medicine, Washington, DC; Department of Neurosurgery (D.M.), Université de Sherbrooke, Quebec, Canada; Pediatric Neurology Division (J.F.K.), Barrow Neurological Institute at Phoenix Children's Hospital, AZ; and Department of Neurosurgery (A.F.), David Geffen School of Medicine at the University of California, Los Angeles; Division of Neurosurgery (A.G.W.), Department of Surgery, Sainte-Justine University Hospital Centre, Montréal; Division of Neurosurgery (A.G.W.), Department of Surgery, University of Montreal Hospital Center (CHUM), Montréal, Québec, Canada.
Background And Objectives: There is a paucity of data directly comparing the outcome of surgical techniques available for the treatment of hypothalamic hamartomas (HHs). This study aims to evaluate the safety and efficacy of commonly used surgical approaches in the treatment of HH-related epilepsy.
Methods: A systematic review and individual participant data (IPD) meta-analysis was conducted.
Laser interstitial thermal therapy in the management of bottom-of-sulcus dysplasia-related epilepsy.
Ann Clin Transl Neurol
December 2024
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Objective: This study assessed the efficacy and safety of magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) versus open surgery (OS) for the treatment of patients with bottom-of-sulcus dysplasia (BOSD)-related epilepsy.
Methods: Twenty-two patients underwent MRgLITT, while 39 underwent OS. Postoperative seizure-free rates were analyzed using Kaplan-Meier curves.
Exploring the efficacy and safety of laser interstitial thermal therapy for recurrent high-grade glioma: the first prospective cohort in China.
Clin Transl Oncol
November 2024
Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
Objective: Recurrent high-grade gliomas are complicated cancers that require additional treatment options. Magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) is a safe method for treating recurrent high-grade glioma; however, its use in China has not been reported. In this study, we aimed to investigate the safety and efficacy of an MRgLITT system (SinoVision™) developed in China for treating recurrent high-grade glioma.
View Article and Find Full Text PDFMagnetic Resonance-Guided Laser Interstitial Thermal Therapy Using Dual-Wavelength Dual-Output Laser Within Two Probe Trajectories for Treatment of Drug-Resistant Epilepsy.
CNS Neurosci Ther
November 2024
Department of Neurosurgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Objective: Magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) is a novel tool and a minimally invasive treatment to drug-resistant epilepsy (DRE). The focus of this research was to evaluate the effectiveness and safety of the newly developed dual-wavelength dual-output MRgLITT system LaserRO within two probe trajectories in treating DRE patients.
Methods: This is a retrospective analysis conducted at a single center, examining patients with DRE who received treatment with the LaserRO MRgLITT system.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!